XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) April 25, 2024
Cyngn Announces Closing of $5.0 Million Firm Commitment Public Offering of Common Stock April 25, 2024